Atorvastatin Calcium
Product Images NDC 68071-4301

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-4301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

68071 4301 09

68071 4301 09
This text is a warning label for a medication called Atorvastatin Calcium 10mg, which is manufactured by NuCare Pharmaceuticals. It includes information on the lot number, expiration date, and ingredients, as well as a warning to keep the medication out of reach of children and store at a controlled temperature. It also advises to call a doctor for medical advice about side effects and provides a contact number for reporting side effects to the FDA.*
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
The text appears to be a medical graph showing the cumulative hazard percentage for the prescription drug Atorvastatin over a four year period. The hazard percentage reaches 15% at the highest point and 10% at the lowest point. The graph also indicates a hazard ratio of 0.53 and a confidence interval of 0.45-0.83. The x-axis shows the time to the first primary endpoint through four years of follow up.*
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
The text represents a study's image or chart, revealing the percentage of subjects who experience Evert (with no clear definition of what Evert is) over time (measured in years) while taking two different medication options. The medication options are Horvastatin 10 mg and Sorvastatin 80 mg. The study found that Horvastatin had a lower risk for the occurrence of Evert with a hazard ratio of 0.78 compared to Sorvastatin. Additionally, the P-value associated with this result was 0.002 which is statistically significant.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.